StemRIM (4599.T) Stock
StemRIM

Company profile
StemRIM reports about 48 full-time employees.
What stands out
- Revenue fell 100.0% in fiscal year 2024, from 2.35 billion JPY in fiscal year 2023, after a rise of 10128.1% the year before.
- It reported a net loss of 2.02 billion JPY in fiscal year 2024, after a profit of 168.35 million JPY in fiscal year 2023.
- It reported no revenue in fiscal year 2024; it spent 1.45 billion JPY on research and development.
Figures from company filings; latest fiscal year ended July 31, 2024.
About StemRIM
StemRIM, a biotechnology company, researches and develops regeneration-inducing medicine in Japan and internationally. The company offers TRIM2, a peptide drug, which is in Phase II clinical trials for the treatment of epidermolysis bullosa, acute ischemic stroke, cerebral infarction, myocardial infarction/cardiomyopathy, chronic liver disease, and knee osteoarthritis. It also develops TRIM3 and TRIM4 for the treatment of various tissue damage diseases; and TRIM5, a molecule for tissue repair, as well as SR-GT1, a gene therapy for the treatment of epidermolysis bullosa. The company was incorporated in 2006 and is headquartered in Ibaraki, Japan.
Largest shareholders
- Katsuto Tamai15.92 %15.92%
- Keiko Tamai8.615 %8.62%
- Kensuke Tomita7.999 %8.00%
- Shionogi & Co., Ltd.7.42%
- Daisuke Gomi5.392 %5.39%
Share of the company, as of May 19, 2026
Leadership
- Masatsune Okajima — President, CEO & Representative Director, 57
- Katsuto Tamai — Founder, GM of Basic Research Department, Chief Scientific Officer & Chairman, 65
- Takehiko Yamazaki VIII — Exec. Officer, Head of Seeds Discovery Dept., Pharma. Research Dept. & Intellectual Property Dept., 55
What companies are similar to StemRIM?
Listed companies of a similar size in the same industry (multi-therapeutic drug manufacturing) include Aska Pharmaceutical Holdings Co.,Ltd. (4886.T), Kyorin Pharmaceutical Co., Ltd. (4569.T), Fuji Pharma Co., Ltd. (4554.T), Solasia Pharma K.k. (4597.T).
How has StemRIM's revenue changed over the last 5 fiscal years?
Revenue by fiscal year: FY2020, 2.10 billion JPY; FY2021, 1.40 billion JPY; FY2022, 22.98 million JPY; FY2023, 2.35 billion JPY; FY2024, 0 JPY.
Has StemRIM made a profit in recent years?
Net income by fiscal year: FY2020, 347.76 million JPY; FY2021, a loss of 582.45 million JPY; FY2022, a loss of 1.95 billion JPY; FY2023, 168.35 million JPY; FY2024, a loss of 2.02 billion JPY. It reported a net loss in 3 of these 5 years.
Company Information
Data as of .
How to cite: DataPorium, “StemRIM (4599.T)”, data as of May 19, 2026, https://dataporium.tech/stocks/4599.T